

Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029

<https://marketpublishers.com/r/PA412A8355E1EN.html>

Date: January 2025

Pages: 446

Price: US\$ 4,950.00 (Single User License)

ID: PA412A8355E1EN

Abstracts

The global Precision Diagnostics and Medicine market is projected to reach USD 246.66 billion in 2029 from USD 145.53 billion by 2024, at a CAGR of 11.1% during the forecast period. Factors such as the ongoing integration of advanced technologies such as artificial intelligence and machine learning to enhance precision medicine development, supported by the rising collaboration and investments by major pharmaceutical and diagnostics companies to develop better precision medicine solutions are supporting the growth of the market. Moreover, the expanding focus of these companies to develop precision therapies and diagnostic tests for multiple diseases such as neurodegenerative and autoimmune diseases highlight the growing importance of precision medicine in healthcare. Additionally, the increasing awareness of patients regarding their health is supporting the adoption of wearable medical devices and direct-to-consumer precision diagnostic tests offering growth opportunities to players in this market. However, the high cost of precision healthcare and challenges associated with the integration and management of big data in healthcare are expected to restrain the growth of this market.

“The monoclonal antibodies segment registered the highest growth rate in the precision medicine market, by products, during the forecast period”

In 2023, the monoclonal antibodies segment registered the highest growth rate within

the precision medicine market by products. Factors such as the increasing collaborations to develop advanced monoclonal antibodies and advancements in antibody engineering technologies are attributed to the growth of this segment. Additionally, these modalities offer various advantages over traditional drugs such as high specificity, low toxicity, and longer-lasting effects among others increasing the adoption of these drug modalities for the treatment of cancer, autoimmune, and infectious diseases supporting the growth of this segment.

“The hospitals and clinics end user segment registered the highest growth rate and largest market share in the precision medicine market, by end user, during the forecast period”

The hospitals and clinic end users registered the highest growth rate within the precision medicine market by end user segment during the forecast period. Factors such as the growing demand for personalized treatments and the ability of hospitals and clinics to offer personalized therapies in a controlled environment can be attributed to the large share of this end user segment. Moreover, the rising collaborations between hospitals and pharmaceutical and diagnostic companies to develop personalized therapies and diagnostic tests support the growth of this segment. Hospitals and clinics act as data reservoirs for these companies which gather real-world data from these institutions for the development of advanced precision solutions. This high growth is projected to continue during the forecast period.

“Asia Pacific: The fastest growing region in the Precision Diagnostics market”

The precision diagnostics market of Asia Pacific is projected to register the highest growth rate during the forecast period. This high growth is attributed to the rising cases of chronic diseases, cancer, and genetic disorders in this region leading to a growing demand for precision diagnostics solutions. This growth is supported by investments in healthcare infrastructure across countries like China, India, and Japan, enhancing access to advanced diagnostic technologies. Additionally, the adoption of technologies like next-generation sequencing (NGS), artificial intelligence, and machine learning is driving innovations in the field. Government initiatives and improved healthcare coverage also contribute to expanding access to precision diagnostics. Moreover, the support and funding from government organizations for life sciences research and development also support the rapid growth of the Asia Pacific precision diagnostics market.

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1 – 44%, Tier 2 – 32%, and Tier 3 – 24%

By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and(Executives) - 25%

By Region: North America -40%, Europe -25%, Asia-Pacific -20%, ROW -15%

List of Companies Profiled in the Report:

Merck & Co., Inc. (US)

F. Hoffmann-La Roche Ltd (Switzerland)

Agilent Technologies, Inc. (US)

Thermo Fisher Scientific Inc. (US)

Myriad Genetics, Inc. (US)

Guardant Health (US)

Abbott (US)

Natera Inc. (US)

Illumina, Inc. (US)

Danaher (US)

Exact Sciences Corporation (US)

Qiagen (Netherlands)

23andME, INC. (US)

ARUP Laboratories. (US)

Devyser (Sweden)

Diasorin S.P.A. (Italy)

Tempus (US)

Pillar Biosciences Inc. (US)

Invivoscribe, Inc. (US)

NeuroCode (US)

C?N Diagnostics (US)

Trinity Biotech Plc. (Ireland)

Amoy Diagnostics Co., Ltd. (China)

Novartis AG (Switzerland)

Bristol-Myers Squibb Company (US)

Gilead Sciences, Inc. (US)

AstraZeneca (UK)

AbbVie Inc. (US)

Eli Lilly and Company. (US)

Pfizer Inc. (US), GSK plc. (UK)

Sanofi (France)

Johnson & Johnson Services, Inc. (US)

Vertex Pharmaceuticals Incorporated (US)

Amgen Inc. (US)

Merck KGaA (Germany)

Sarepta Therapeutics, Inc. (US).

Research Coverage:

This report provides a detailed picture of the global Precision Diagnostics and Medicine Market. It aims to estimate the size and future growth potential of the market across different segments such as the precision diagnostics market (type, indication, and end user) and precision medicine market (product, indication, and end user) region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the precision diagnostics and medicine market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product launches, mergers and acquisitions, and recent developments associated with the precision diagnostics and medicine market. Competitive analysis of upcoming startups in the precision diagnostics and medicine market ecosystem is covered in this report.

Reasons to buy this report :

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall precision diagnostics and medicine market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

Analysis of key drivers (Increasing Integration Of AI And ML To Improve Precision Diagnostics And Therapy Development, Rising Collaborations Between Pharmaceutical And Diagnostics Company To Enhance Precision Healthcare and Rise in direct-to-consumer testing), restraints (High costs of precision healthcare and Slow Pace Of Reimbursement For Precision Diagnostics), opportunities (Expanding The Application Of Precision Diagnostics From Oncology and Integration of wearable devices to enhance precision

healthcare), and challenges (Challenges in Regulatory Approval for Diagnostics and Big Data Management and Integration) influencing the growth of the precision diagnostics and medicine market.

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches and approvals in the precision diagnostics and medicine market

Market Development: Comprehensive information about lucrative markets – the report analyses the precision diagnostics and medicine market across varied regions.

Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the precision diagnostics and medicine market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players in precision diagnostics market like- F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Agilent Technologies, Inc. (US), Guardant Health (US), Thermo Fisher Scientific Inc. (US), Myriad Genetics, Inc. (US) among others and precision medicine market like- Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US) Gilead Sciences, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Novartis AG (Switzerland), among others.

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
 - 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
 - 1.3.2 INCLUSIONS AND EXCLUSIONS
 - 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 SECONDARY DATA
 - 2.1.2 PRIMARY DATA
- 2.2 MARKET SIZE ESTIMATION METHODOLOGY
 - 2.2.1 PRECISION DIAGNOSTICS MARKET
 - 2.2.2 PRECISION MEDICINE MARKET
 - 2.2.3 INSIGHTS FROM PRIMARY SOURCES
- 2.3 TOP-DOWN APPROACH
 - 2.3.1 PRECISION DIAGNOSTICS MARKET
 - 2.3.2 PRECISION MEDICINE MARKET
- 2.4 GROWTH FORECAST MODEL
- 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.6 RESEARCH ASSUMPTIONS
- 2.7 RESEARCH LIMITATIONS
- 2.8 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

- 4.1 PRECISION DIAGNOSTICS MARKET OVERVIEW
- 4.2 PRECISION MEDICINE MARKET OVERVIEW
- 4.3 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE AND

COUNTRY, 2023

4.4 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029

4.5 PRECISION DIAGNOSTICS MARKET, BY END USER, 2023

4.6 NORTH AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT AND COUNTRY, 2023

4.7 PRECISION MEDICINE MARKET, BY INDICATION, 2024 VS. 2029

4.8 PRECISION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4.9 PRECISION MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.1.1 Increasing collaborations between pharmaceutical and diagnostic companies

5.2.1.2 Rise in direct-to-consumer testing

5.2.1.3 Growing integration of artificial intelligence and machine learning

5.2.2 RESTRAINTS

5.2.2.1 High cost of precision healthcare

5.2.3 OPPORTUNITIES

5.2.3.1 Expanding applications of precision healthcare

5.2.3.2 Growing adoption of wearable devices

5.2.4 CHALLENGES

5.2.4.1 Complex regulatory approval landscape

5.2.4.2 Big data management and integration issues

5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

5.4 PRICING ANALYSIS

5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER

5.4.2 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER

5.4.3 AVERAGE SELLING PRICE TREND, BY REGION

5.5 VALUE CHAIN ANALYSIS

5.5.1 PRECISION DIAGNOSTICS MARKET

5.5.2 PRECISION MEDICINE MARKET

5.6 SUPPLY CHAIN ANALYSIS

5.6.1 PRECISION DIAGNOSTICS MARKET

5.6.2 PRECISION MEDICINE MARKET

5.7 ECOSYSTEM ANALYSIS

5.8 PIPELINE ANALYSIS

5.9 DIAGNOSTIC PRODUCT ANALYSIS

5.10 INVESTMENT/FUNDING ACTIVITY

5.11 TECHNOLOGY ANALYSIS

5.11.1 KEY TECHNOLOGIES

5.11.1.1 Next-generation sequencing

5.11.1.2 Immunohistochemistry

5.11.1.3 Liquid biopsy

5.11.2 COMPLEMENTARY TECHNOLOGIES

5.11.2.1 Single-cell analysis

5.11.2.2 AI and ML integration

5.11.3 ADJACENT TECHNOLOGIES

5.11.3.1 Theranostics

5.11.3.2 Imaging technologies

5.12 PATENT ANALYSIS

5.13 TRADE ANALYSIS

5.13.1 IMPORT DATA

5.13.2 EXPORT DATA

5.14 KEY CONFERENCES AND EVENTS, 2025–2026

5.15 REGULATORY LANDSCAPE

5.15.1 REGULATORY ANALYSIS

5.15.1.1 North America

5.15.1.2 Europe

5.15.1.3 Asia Pacific

5.15.1.4 Rest of the World

5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.16 PORTER'S FIVE FORCES ANALYSIS

5.16.1 PRECISION DIAGNOSTICS MARKET

5.16.1.1 Threat of new entrants

5.16.1.2 Threat of substitutes

5.16.1.3 Bargaining power of buyers

5.16.1.4 Bargaining power of suppliers

5.16.1.5 Intensity of competitive rivalry

5.16.2 PRECISION MEDICINE MARKET

5.16.2.1 Threat of new entrants

5.16.2.2 Threat of substitutes

5.16.2.3 Bargaining power of buyers

5.16.2.4 Bargaining power of suppliers

5.16.2.5 Intensity of competitive rivalry

5.17 KEY STAKEHOLDERS AND BUYING CRITERIA

5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS

5.17.2 BUYING CRITERIA

5.18 IMPACT OF AI/GEN AI ON PRECISION DIAGNOSTICS AND MEDICINE MARKET

5.18.1 INTRODUCTION

5.18.2 MARKET POTENTIAL OF PRECISION DIAGNOSTICS AND MEDICINES

5.18.3 AI USE CASES

5.18.4 KEY COMPANIES IMPLEMENTING AI

5.18.5 FUTURE OF GENERATIVE AI ON PRECISION DIAGNOSTICS AND MEDICINE ECOSYSTEM

6 PRECISION DIAGNOSTICS MARKET, BY TYPE

6.1 INTRODUCTION

6.2 GENETIC TESTING

6.2.1 NEED TO DETECT HEREDITARY AND RARE DISEASES TO STIMULATE GROWTH

6.3 DTC TESTING

6.3.1 INCREASED AWARENESS ABOUT PERSONALIZED HEALTH TO ENCOURAGE GROWTH

6.4 OTHER TYPES

7 PRECISION DIAGNOSTICS MARKET, BY INDICATION

7.1 INTRODUCTION

7.2 ONCOLOGY

7.2.1 RISING CANCER CASES TO ACCELERATE GROWTH

7.3 NEUROLOGY

7.3.1 INCREASING DEVELOPMENT OF PRECISION DIAGNOSTIC TESTS FOR NEUROLOGICAL DISEASES TO FUEL MARKET

7.4 IMMUNOLOGY

7.4.1 GROWING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIAGNOSTIC TOOLS TO DRIVE MARKET

7.5 OTHER DIAGNOSTIC INDICATIONS

8 PRECISION DIAGNOSTICS MARKET, BY END USER

8.1 INTRODUCTION

8.2 CLINICAL LABORATORIES

8.2.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO FACILITATE GROWTH

8.3 HOSPITALS

8.3.1 GROWING COLLABORATIONS AMONG DIAGNOSTIC MANUFACTURING COMPANIES TO DRIVE MARKET

8.4 HOME CARE SETTINGS

8.4.1 INCREASING DEMAND FOR AT-HOME DIAGNOSTIC TESTS TO SPUR GROWTH

9 PRECISION MEDICINE MARKET, BY PRODUCT

9.1 INTRODUCTION

9.2 MONOCLONAL ANTIBODIES

9.2.1 RISING ADOPTION OF ONCOLOGY AND AUTOIMMUNE THERAPIES TO SUPPORT GROWTH

9.3 INHIBITOR DRUGS

9.3.1 INCREASING FDA APPROVALS FOR NOVEL INHIBITORS TO CONTRIBUTE TO GROWTH

9.4 CELL & GENE THERAPIES

9.4.1 GROWING INVESTMENTS IN GENETIC DISORDER RESEARCH TO FUEL MARKET

9.5 ANTIVIRAL & ANTI-RETROVIRAL DRUGS

9.5.1 NEED TO TARGET VIRAL INFECTIONS AND PREVENT VIRUS SPREAD TO FACILITATE GROWTH

9.6 OTHER PRODUCTS

10 PRECISION MEDICINE MARKET, BY INDICATION

10.1 INTRODUCTION

10.2 ONCOLOGY

10.2.1 GROWING EMPHASIS ON DEVELOPING PRECISION CANCER THERAPIES TO BOOST MARKET

10.3 RARE DISEASES

10.3.1 SHIFTING FOCUS ON TARGETED TREATMENT TO FAVOR GROWTH

10.4 INFECTIOUS DISEASES

10.4.1 NEED TO ENHANCE EFFICACY OF TREATMENTS TO DRIVE MARKET

10.5 HEMATOLOGICAL DISORDERS

10.5.1 INCREASING RESEARCH ON DEVELOPING PERSONALIZED THERAPIES
TO AUGMENT GROWTH

10.6 OTHER MEDICINE INDICATIONS

11 PRECISION MEDICINE MARKET, BY END USER

11.1 INTRODUCTION

11.2 HOSPITALS & CLINICS

11.2.1 GROWING FOCUS ON PRECISION THERAPIES TO FUEL MARKET

11.3 HOME CARE SETTINGS

11.3.1 INCREASING PREFERENCE FOR SELF-ADMINISTRATION TECHNIQUES
TO EXPEDITE GROWTH

12 PRECISION DIAGNOSTICS AND MEDICINE MARKET, BY REGION

12.1 INTRODUCTION

12.2 NORTH AMERICA

12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

12.2.2 US

12.2.2.1 Well-established infrastructure and availability of advanced treatments to
augment growth

12.2.3 CANADA

12.2.3.1 Growing cancer burden to support growth

12.3 EUROPE

12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

12.3.2 GERMANY

12.3.2.1 Growing collaborations between research institutions and healthcare
providers to boost market

12.3.3 UK

12.3.3.1 Favorable government support to expedite growth

12.3.4 FRANCE

12.3.4.1 Growing preference for personalized medicine to fuel market

12.3.5 ITALY

12.3.5.1 Rise in genomics research and diagnostic testing to foster growth.

12.3.6 SPAIN

12.3.6.1 Robust network of healthcare systems, research centers, and universities to
facilitate growth

12.3.7 REST OF EUROPE

12.4 ASIA PACIFIC

12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

12.4.2 CHINA

12.4.2.1 Growing regulatory approvals for precision medicines to boost market

12.4.3 JAPAN

12.4.3.1 Increasing availability of health insurance to encourage growth

12.4.4 INDIA

12.4.4.1 Rising burden of chronic diseases to promote growth

12.4.5 AUSTRALIA

12.4.5.1 Booming research & development investments to spur growth

12.4.6 REST OF ASIA PACIFIC

12.5 LATIN AMERICA

12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

12.5.2 BRAZIL

12.5.2.1 Growing incorporation of genomic medicine into public healthcare to drive market

12.5.3 MEXICO

12.5.3.1 Booming biopharmaceutical sector to contribute to growth

12.5.4 REST OF LATIN AMERICA

12.6 MIDDLE EAST & AFRICA

12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

13.1 OVERVIEW

13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2024

13.2.1 PRECISION DIAGNOSTICS MARKET

13.2.2 PRECISION MEDICINE MARKET

13.3 REVENUE ANALYSIS, 2021–2023

13.3.1 PRECISION DIAGNOSTICS MARKET

13.3.2 PRECISION MEDICINE MARKET

13.4 MARKET SHARE ANALYSIS, 2023

13.4.1 PRECISION DIAGNOSTICS MARKET

13.4.2 PRECISION MEDICINE MARKET

13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023

13.5.1 PRECISION DIAGNOSTICS MARKET

13.5.1.1 Stars

13.5.1.2 Emerging leaders

13.5.1.3 Pervasive players

13.5.1.4 Participants

- 13.5.1.5 Company footprint: Key players, 2023
 - 13.5.1.5.1 Company footprint
 - 13.5.1.5.2 Region footprint
 - 13.5.1.5.3 Type footprint
 - 13.5.1.5.4 Indication footprint
- 13.5.2 PRECISION MEDICINE MARKET
 - 13.5.2.1 Stars
 - 13.5.2.2 Emerging leaders
 - 13.5.2.3 Pervasive players
 - 13.5.2.4 Participants
 - 13.5.2.5 Company footprint: Key players, 2023
 - 13.5.2.5.1 Company footprint
 - 13.5.2.5.2 Region footprint
 - 13.5.2.5.3 Product footprint
 - 13.5.2.5.4 Indication footprint
- 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
 - 13.6.1 PRECISION DIAGNOSTICS MARKET
 - 13.6.1.1 Progressive companies
 - 13.6.1.2 Responsive companies
 - 13.6.1.3 Dynamic companies
 - 13.6.1.4 Starting blocks
 - 13.6.1.5 Competitive benchmarking
 - 13.6.1.5.1 Detailed list of key startups/SMES
 - 13.6.1.5.2 Competitive benchmarking of startups/SMEs
 - 13.6.2 PRECISION MEDICINE MARKET
 - 13.6.2.1 Progressive companies
 - 13.6.2.2 Responsive companies
 - 13.6.2.3 Dynamic companies
 - 13.6.2.4 Starting blocks
 - 13.6.2.5 Competitive benchmarking
 - 13.6.2.5.1 Detailed list of key startups/SMES
 - 13.6.2.5.2 Competitive benchmarking of startups/SMEs
- 13.7 COMPANY VALUATION AND FINANCIAL METRICS
 - 13.7.1 PRECISION DIAGNOSTICS MARKET
 - 13.7.2 PRECISION MEDICINE MARKET
- 13.8 BRAND/PRODUCT COMPARISON
- 13.9 PRECISION DIAGNOSTICS MARKET: COMPETITIVE SCENARIO
 - 13.9.1 PRODUCT LAUNCHES AND APPROVALS
 - 13.9.2 DEALS

13.9.3 EXPANSIONS

13.10 PRECISION MEDICINE MARKET: COMPETITIVE SCENARIO

13.10.1 PRODUCT LAUNCHES AND APPROVALS

13.10.2 DEALS

13.10.3 EXPANSIONS

14 COMPANY PROFILES

14.1 KEY PLAYERS

14.1.1 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS)

14.1.1.1 Business overview

14.1.1.2 Products offered

14.1.1.3 Recent developments

14.1.1.3.1 Product launches and approvals

14.1.1.3.2 Deals

14.1.1.4 MnM view

14.1.1.4.1 Key strengths

14.1.1.4.2 Strategic choices

14.1.1.4.3 Weaknesses and competitive threats

14.1.2 ABBOTT

14.1.2.1 Business overview

14.1.2.2 Products offered

14.1.2.3 Recent developments

14.1.2.3.1 Deals

14.1.2.4 MnM view

14.1.2.4.1 Key strengths

14.1.2.4.2 Strategic choices

14.1.2.4.3 Weaknesses and competitive threats

14.1.3 AGILENT TECHNOLOGIES, INC.

14.1.3.1 Business overview

14.1.3.2 Products offered

14.1.3.3 Recent developments

14.1.3.3.1 Product launches and approvals

14.1.3.3.2 Deals

14.1.3.3.3 Expansions

14.1.3.4 MnM view

14.1.3.4.1 Key strengths

14.1.3.4.2 Strategic choices

14.1.3.4.3 Weaknesses and competitive threats

14.1.4 GUARDANT HEALTH

14.1.4.1 Business overview

14.1.4.2 Products offered

14.1.4.3 Recent developments

14.1.4.3.1 Product launches and approvals

14.1.4.3.2 Deals

14.1.4.4 MnM view

14.1.4.4.1 Key strengths

14.1.4.4.2 Strategic choices

14.1.4.4.3 Weaknesses and competitive threats

14.1.5 EXACT SCIENCES CORPORATION

14.1.5.1 Business overview

14.1.5.2 Products offered

14.1.5.3 Recent developments

14.1.5.3.1 Product launches and approvals

14.1.5.3.2 Deals

14.1.5.4 MnM view

14.1.5.4.1 Key strengths

14.1.5.4.2 Strategic choices

14.1.5.4.3 Weaknesses and competitive threats

14.1.6 QIAGEN

14.1.6.1 Business overview

14.1.6.2 Products offered

14.1.6.3 Recent developments

14.1.6.3.1 Product launches and approvals

14.1.6.3.2 Deals

14.1.7 MYRIAD GENETICS, INC.

14.1.7.1 Business overview

14.1.7.2 Products offered

14.1.7.3 Recent developments

14.1.7.3.1 Product launches and approvals

14.1.7.3.2 Deals

14.1.7.3.3 Other developments

14.1.8 NATERA, INC.

14.1.8.1 Business overview

14.1.8.2 Products offered

14.1.8.3 Recent developments

14.1.8.3.1 Product launches and approvals

14.1.8.3.2 Deals

14.1.9 ILLUMINA, INC.

- 14.1.9.1 Business overview
- 14.1.9.2 Products offered
- 14.1.9.3 Recent developments
 - 14.1.9.3.1 Product launches and approvals
 - 14.1.9.3.2 Deals

14.1.10 THERMO FISHER SCIENTIFIC INC.

- 14.1.10.1 Business overview
- 14.1.10.2 Products offered
- 14.1.10.3 Recent developments
 - 14.1.10.3.1 Product launches and approvals
 - 14.1.10.3.2 Deals

14.1.11 DANAHER

- 14.1.11.1 Business overview
- 14.1.11.2 Products offered
- 14.1.11.3 Recent developments
 - 14.1.11.3.1 Product launches and approvals
 - 14.1.11.3.2 Deals

14.1.12 23ANDME, INC.

- 14.1.12.1 Business overview
- 14.1.12.2 Products offered
- 14.1.12.3 Recent developments
 - 14.1.12.3.1 Deals

14.1.13 MERCK & CO., INC.

- 14.1.13.1 Business overview
- 14.1.13.2 Products offered
- 14.1.13.3 Recent developments
 - 14.1.13.3.1 Product launches and approvals
 - 14.1.13.3.2 Deals

14.1.14 GILEAD SCIENCES, INC.

- 14.1.14.1 Business overview
- 14.1.14.2 Products offered
- 14.1.14.3 Recent developments
 - 14.1.14.3.1 Product launches and approvals
 - 14.1.14.3.2 Deals

14.1.15 F. HOFFMANN-LA ROCHE LTD (MEDICINE)

- 14.1.15.1 Business overview
- 14.1.15.2 Products offered
- 14.1.15.3 Recent developments

- 14.1.15.3.1 Product launches and approvals
- 14.1.16 BRISTOL-MYERS SQUIBB COMPANY
 - 14.1.16.1 Business overview
 - 14.1.16.2 Products offered
 - 14.1.16.3 Recent developments
 - 14.1.16.3.1 Product launches and approvals
 - 14.1.16.3.2 Deals
- 14.1.17 NOVARTIS AG
 - 14.1.17.1 Business overview
 - 14.1.17.2 Products offered
 - 14.1.17.3 Recent developments
 - 14.1.17.3.1 Product launches and approvals
 - 14.1.17.3.2 Deals
- 14.1.18 ASTRAZENECA
 - 14.1.18.1 Business overview
 - 14.1.18.2 Products offered
 - 14.1.18.3 Recent developments
 - 14.1.18.3.1 Product launches and approvals
 - 14.1.18.3.2 Deals
- 14.1.19 ABBVIE INC.
 - 14.1.19.1 Business overview
 - 14.1.19.2 Products offered
 - 14.1.19.3 Recent developments
 - 14.1.19.3.1 Product launches and approvals
 - 14.1.19.3.2 Deals
 - 14.1.19.3.3 Expansions
- 14.1.20 LILLY
 - 14.1.20.1 Business overview
 - 14.1.20.2 Products offered
 - 14.1.20.3 Recent developments
 - 14.1.20.3.1 Product launches and approvals
 - 14.1.20.3.2 Deals
- 14.1.21 PFIZER INC.
 - 14.1.21.1 Business overview
 - 14.1.21.2 Products offered
 - 14.1.21.3 Recent developments
 - 14.1.21.3.1 Product launches and approvals
 - 14.1.21.3.2 Deals
- 14.1.22 SAREPTA THERAPEUTICS, INC.

- 14.1.22.1 Business overview
- 14.1.22.2 Products offered
- 14.1.22.3 Recent developments
 - 14.1.22.3.1 Product launches and approvals
 - 14.1.22.3.2 Deals

14.1.23 VERTEX PHARMACEUTICALS INCORPORATED

- 14.1.23.1 Business overview
- 14.1.23.2 Products offered
- 14.1.23.3 Recent developments
 - 14.1.23.3.1 Product launches and approvals
 - 14.1.23.3.2 Deals

14.1.24 GSK PLC.

- 14.1.24.1 Business overview
- 14.1.24.2 Products offered
- 14.1.24.3 Recent developments
 - 14.1.24.3.1 Product launches and approvals
 - 14.1.24.3.2 Deals

14.2 OTHER PLAYERS

- 14.2.1 SANOFI
- 14.2.2 JOHNSON & JOHNSON SERVICES, INC.
- 14.2.3 AMGEN INC.
- 14.2.4 MERCK KGAA
- 14.2.5 ALNYLAM PHARMACEUTICALS, INC.
- 14.2.6 INCYTE
- 14.2.7 ARUP LABORATORIES
- 14.2.8 DEVYSER
- 14.2.9 DIASORIN S.P.A.
- 14.2.10 TEMPUS
- 14.2.11 PILLAR BIOSCIENCES INC.
- 14.2.12 INVIVOSCRIBE, INC.
- 14.2.13 NEUROCODE
- 14.2.14 C?N DIAGNOSTICS
- 14.2.15 TRINITY BIOTECH
- 14.2.16 AMOY DIAGNOSTICS CO., LTD.

15 APPENDIX

15.1 DISCUSSION GUIDE

15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

15.3 CUSTOMIZATION OPTIONS

15.4 RELATED REPORTS

15.5 AUTHOR DETAILS

I would like to order

Product name: Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC),
Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products
(Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global
Forecast to 2029

Product link: <https://marketpublishers.com/r/PA412A8355E1EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/PA412A8355E1EN.html>